secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001628280-25-039770
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma raises $60M, CEO and CFO resign, new leadership team appointed
------------------------------------------------------------------------

- Private placement of 11,040,776 shares at $1.42/share and pre-funded warrants for 31,234,731 shares for ~$60M gross.
- CEO Paula Ragan, Ph.D., and CFO Adam S. Mostafa resigned effective Aug 12, 2025; no disagreement cited.
- Adam Raymond Craig, M.D., Ph.D., appointed Executive Chairman and principal executive officer; John Volpone named President.
- David H. Kirske appointed CFO, Secretary, principal financial and accounting officer.
- Proceeds to fund continued development of mavorixafor for chronic neutropenia and commercialization for WHIM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025039770/0001628280-25-039770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828025039770/xfor-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-039770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer